Navigation Links
United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the United States Securities and Exchange Commission has declared effective its Registration Statement on Form S-4 filed with the Commission. The Registration Statement, including the joint proxy statement, is being used in connection with NeoStem's acquisition of China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP). It is anticipated that this acquisition will expand the capabilities and worldwide reach of NeoStem. China Biopharmaceutical's primary asset is a 51% ownership interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"), located in Suzhou, China which in 2008 generated gross revenues of approximately $50 million (US) and net income of approximately $8,000,000 (US). NeoStem's 51% controlling interest in Erye will enable it to benefit from the over 100 drugs on seven GMP lines, including small molecule drugs being manufactured by Erye. Erye has been in business for more than 50 years and is respected for its quality, service and reliability. Erye has begun its three year expansion and relocation program which is anticipated to enhance revenues, profits, and manufacturing capabilities in one of the fastest growing medical markets, the Peoples Republic of China.

The acquisition is subject to customary closing conditions, including approval by the shareholders of each company at meetings of shareholders scheduled for October 29, 2009. Robin Smith, MD, CEO of NeoStem further commented, "We are excited to bring this transaction to our shareholders for a vote and, subject to their approval, begin our collaboration with Suzhou Erye Pharmaceutical Co. Ltd. as we believe it will open new markets, distrib
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army
3. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
4. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
7. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
8. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
11. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
(Date:7/29/2014)... Cat: Can a particle be separated from its properties? ... , published the results of the first Cheshire Cat ... by Chapman University in Orange, CA, and Vienna University ... cat without a grin," thought Alice in Wonderland, "but ... thing I ever saw in my life!" Alice,s surprise ...
(Date:7/29/2014)... 29, 2014 Second generation biofuels are a ... fossil fuels. However, as natural gas is very cheap, this ... are not as valuable as they could be in comparison ... financing projects, has made it difficult for renewable energy developers ... off the ground. For these reasons, certain companies have shifted ...
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... research team co-led by scientists from the J. Craig Venter ... of Maryland School of Medicine, today published the sequence and ... in Nature Biotechnology . Agnes P. Chan, Ph.D., JCVI, ... paper describing the 4.5X coverage of this important oilseed crop. ...
... In Vitro Toxicology Services -- MACCLESFIELD, England, August 20, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... SLN), a leading international RNAi therapeutics company, is pleased ... has announced the grant of an option to Novartis ... commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which ... conducting a Phase II clinical trial of QPI-1002 for ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Cyprotex Adds In Vitro Toxicology Services 2Cyprotex Adds In Vitro Toxicology Services 3Cyprotex Adds In Vitro Toxicology Services 4Cyprotex Adds In Vitro Toxicology Services 5Cyprotex Adds In Vitro Toxicology Services 6Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... Amundsen reached the South Pole in 1911, but new ... any human. , Using data from 16 ice cores ... including the South Pole, a group led by Joe ... Nevada, created the most accurate and precise reconstruction to ... new record, described in an article published today in ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... time when research funding is hard to come by, a ... landed almost $5.5 million in National Institutes of Health highly ... $3.6 million over five years is aimed at determining whether ... of hemophilia A more effective. The second grant worth $2 ...
... will be floating high above the Gulf of Mexico ... DNA analysis instrument developed at Tech that could benefit ... of mechanical engineering, and Collin Tranter, a graduate student ... instrument could be used to monitor the health of ...
... to react when their animals start behaving abnormally. The ... the symptoms are so variable. In some cases the ... which is generally considered to be how most cats spend ... is followed by twitching of facial muscles, chewing and swallowing ...
Cached Biology News:Hemophilia research gets NIH boost to a tune of $5.5 million 2Hemophilia research gets NIH boost to a tune of $5.5 million 3Louisiana Tech University researchers, NASA partner to conduct zero-gravity experiments 2Seizing the opportunity: treating epilepsy in cats 2
Request Info...
... Universal Amplicon Detection Assay (ADA) ... the qualitative detection and quantitation ... in vitro nucleic acid amplification. ... to be used in diagnostic ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... ready-to-use reagents for the isolation of genomic ... for the isolation of genomic DNA from ... for the isolation of genomic DNA from ... can be used for restriction endonuclease digestion ...
Biology Products: